Administration of Cucurbitacin B (CuB) to lung cancer patients was shown to decrease the numbers of bona fide MDSCs (Lin− HLA-DR− CD33+), while it increased the numbers of mature Lin- HLA-DR+ CD33+ myeloid cells in peripheral blood. Here, CD33 is linked to lung carcinoma.